GeneSpark Diagnostics
PrivateLast Round
Series B
Aug 6, 2020
Total Funding Raised
$28.4M
Company Overview
GeneSpark Diagnostics operates in Healthcare & Life Sciences and is based in Branford, Connecticut. Its latest recorded funding round was a Series B round in August 2020.
GeneSpark Diagnostics is a molecular diagnostics company that develops rapid, portable, and point-of-care diagnostic platforms for infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GeneSpark Diagnostics Comparables
Compare GeneSpark Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| U Star Biochemical Technologies, Inc. | 80% | |
| binx health | 77% | |
| Danaher | 77% |
For institutional investors. Book with your work email.
GeneSpark Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 6, 2020 | ||||
| Grant | Jun 29, 2020 | ||||
| Grant | May 5, 2020 | ||||
| Grant | Apr 20, 2020 | ||||
| Series A | Jun 20, 2019 | ||||
Grant | Nov 20, 2017 |
For institutional investors. Book with your work email.
GeneSpark Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| VC23 Investors | Series B, Series A |
| Connecticut Innovations | Series B, Series A |
| Parvizi Surgical Innovation | Series B |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Leading Edge Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2020
$696K grant from Public Health Emergency Medical Countermeasures Enterprise.
- Jun 20, 2019
$9M round led by Connecticut Innovations
For institutional investors. Book with your work email.
GeneSpark Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GeneSpark Diagnostics's valuation, stock price, and market status.
Is GeneSpark Diagnostics a public or private company?
GeneSpark Diagnostics is a private company.
What is the current stock price of GeneSpark Diagnostics?
GeneSpark Diagnostics is a private company, so its shares have no public market price. Caplight tracks GeneSpark Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GeneSpark Diagnostics worth (valuation)?
Valuation information for GeneSpark Diagnostics is not publicly available.
Can I buy GeneSpark Diagnostics stock?
GeneSpark Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GeneSpark Diagnostics's last funding round?
GeneSpark Diagnostics's most recent funding round was Series B on August 6, 2020.
Who are the main investors in GeneSpark Diagnostics?
Key investors in GeneSpark Diagnostics include Connecticut Innovations.
Will GeneSpark Diagnostics IPO soon?
No public IPO plans have been announced for GeneSpark Diagnostics.
How can I track GeneSpark Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in GeneSpark Diagnostics's shares on secondary markets.